NCT01716026View on ClinicalTrials.gov

Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Choroidal Subfoveal/Juxtafoveal Neovascularization in High Myopia
Interventions
DRUG

Bevazizumab intravitreal injection

Intravitreal injection of bevacizumab

Trial Locations (11)

15706

CHUS - Fundacion IDICHUS, Santiago de Compostela

28010

Hospital Clinico Universitario San Carlos, Madrid

28031

Hospital Universitario Ramón y Cajal, Madrid

30100

Hospital Reina Sofia, Murcia

31080

Clinica Universitaria de Navarra, Pamplona

41013

Hospital Virgen de Valme, Seville

41071

Hospital Virgen de la Macarena, Seville

47011

IOBA - Instituto Universitario de Oftalmobiologia Aplicada, Valladolid

47012

Hospital Universitario Rio Hortega, Valladolid

02006

Complejo Hospitalario de Albacete, Albacete

Unknown

Hospital General Universitario de Valencia, Valencia

All Listed Sponsors
lead

Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA

OTHER

NCT01716026 - Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia | Biotech Hunter | Biotech Hunter